The US Food and Drug Administration (FDA) has approved generic everolimus tablets for the treatment of patients with various advanced cancers, including renal cell carcinoma (RCC). Afinitor comes off patent over the next 5 years, after which generic everolimus will become available at a vastly cheaper cost to the NHS. A generic drug is a pharmaceutical drug that contains […]
A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs. Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most […]
We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]
Results from the ENTRATA clinical trial to assess telaglenastat in combination with everolimus for patients with heavily pre-treated renal cell carcinoma were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Telaglenastat is a type of biological therapy called a glutaminase inhibitor that blocks the glutaminase enzyme, which is […]
A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]
The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]
The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here
A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]
Cabozantinib significantly improves overall survival in previously treated patients with advanced renal cell carcinoma (RCC) compared to everolimus, with consistent results after long-term follow-up. Results from a second interim analysis of the phase 3 METEOR trial have been published in the British Journal of Cancer, showing cabozantinib significantly improved overall survival compared with everolimus in […]
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
